FDA Finalizes Potency Guidance for Cell, Gene Therapies

FDA has told cell and gene therapy sponsors how it wants potency proven, and the answer is no longer a single assay run at the end of the line. On November 2, 2026, the agency announced final guidance, “Potency Assurance for Cellular and Gene Therapy Products,” replacing a 2011 standard that focused almost entirely on the final-release test. The Federal Register notice confirming availability ran the next day.

Why the 2011 guidance stopped fitting

The 2011 guidance treated potency as something a sponsor demonstrated with a single, well-characterized assay applied to the finished product. That worked reasonably well for a biologic made the same way, in the same facility, in large lots, release after release. It fits a patient-specific CAR-T product — manufactured from one patient's own cells, in a lot of one, on a clock measured in days — much less comfortably. Sponsors and the Alliance for Regenerative Medicine told FDA as much in comments on the December 2023 draft, and the American Society of Gene and Cell Therapy went further, warning the draft risked adding development burden without giving sponsors the clarity they needed. The final guidance is FDA's answer to that record.

A strategy, not a single test

The guidance's organizing idea is the Potency Assurance Strategy: a plan, built and documented across the product's development, that distributes the burden of proving potency across multiple points rather than concentrating it in one final assay. That spans IND-stage assay development, the design of the manufacturing process itself, in-process controls, lot-release testing, and continued monitoring after approval. FDA frames this as risk-based — the depth of the strategy should track the product's actual risk profile and manufacturing variability, not a fixed template applied uniformly across every modality.

Where the guidance gets specific

• Short-shelf-life products: the guidance addresses the practical problem of generating potency data before a product that cannot be held in reserve has already been infused.
• Viral vector gene therapies: separate recommendations address the vector itself, distinct from the potency of the finished drug product.
• Patient-specific (autologous) therapies: for products made with a viral vector, FDA recommends sponsors demonstrate adequate biological activity for each vector lot before it is used in manufacturing, in addition to potency testing of the final product — an added checkpoint earlier in the chain, where a failure is cheaper to catch than after a patient-specific lot is already complete.

What does not change

The guidance is nonbinding. It states FDA's current thinking on how to satisfy the agency's existing potency requirements under the Public Health Service Act and FDA's biologics regulations; it does not itself create new legal obligations, and a sponsor may propose an alternative approach if it satisfies those underlying requirements. For sponsors already in late-stage development or with an approved product, the practical question is less about compliance on day one and more about whether an existing potency assurance package — built under the prior guidance's assumptions — will need updating to match the strategy FDA has now described in detail.

Frequently asked questions

What did FDA finalize on November 2, 2026?

Final guidance for industry, “Potency Assurance for Cellular and Gene Therapy Products,” announced November 2, 2026, and published as a Federal Register availability notice on November 3, 2026 (91 FR 69259–69261, Document Number 2026-22427), issued by CBER's Office of Therapeutic Products.

What does it replace?

FDA's 2011 guidance on potency tests for cellular and gene therapy products. The final guidance finalizes a December 2023 draft (Docket FDA-2023-D-4299) after FDA considered public comments.

What is the core recommendation?

A risk-based Potency Assurance Strategy spanning development, manufacturing, lot release and postmarket monitoring, rather than reliance on one final-product potency assay.

Does it single out any product types?

Yes: short-shelf-life products, viral vector gene therapies, and patient-specific autologous therapies, including a recommendation to test each viral vector lot's biological activity before use, in addition to final-product testing.

Is the guidance binding?

No. It is nonbinding; it describes FDA's current thinking, and a sponsor may use an alternative approach if it satisfies applicable statutory and regulatory requirements.